Multiple sclerosis, sleep latencies and HLA antigens

Area of Science:

• Neuroimmunology
• Sleep Medicine
• Genetics

Background:

• Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system.
• Early sleep onset, indicated by reduced mean sleep onset latencies (MSOLs), is a potential symptom in MS.
• Human leukocyte antigen (HLA) antigens, specifically HLA-DR2, are implicated in narcolepsy and potentially in MS-related sleep disturbances.

Purpose of the Study:

• To investigate the association between specific HLA antigens and mean sleep onset latencies (MSOLs) in multiple sclerosis (MS) patients.
• To determine if HLA-DR2 or DQw1 antigens are solely responsible for early sleep onset in MS.
• To explore the role of other HLA antigens in MS patients with and without sleep disturbances.

Main Methods:

• A multiple sleep latency test (MSLT) was conducted on 37 MS patients without reported sleep complaints.
• Patients were genotyped for HLA-A, B, C, DR, and DQ antigens.
• Mean sleep onset latencies (MSOLs) were analyzed in relation to the presence of specific HLA antigens.

Main Results:

• Reduced MSOLs were observed in 21 out of 37 MS patients.
• Early sleep onset was noted in 7/15 DR2-positive and 12/21 DQw1-positive patients.
• A significant association was found between reduced MSOLs and HLA-B8 or B14 positivity (13/16 patients).
• No single HLA antigen was over-represented in patients with MSOL > 30 min, but a group of cross-reacting antigens (B5, B15, B18, B21, B35) were associated with longer MSOLs.

Conclusions:

• The study suggests that HLA-DR2 and DQw1 antigens are not the sole determinants of early sleep onset in multiple sclerosis.
• Other HLA antigens, such as B8 and B14, may play a more significant role in reduced MSOLs in MS patients.
• The genetic factors influencing sleep onset in MS are complex and likely involve multiple HLA genes or linked loci.